Mar 7, 2011 | Charles River and BioAtla announce partnership
–Companies collaborate to offer Integrated Biological Service for Preclinical Development–
-
SAN DIEGO, Calif. Charles River and BioAtla have recently partnered to create an integrated biological service for antibodies and other protein therapeutics designed to accelerate drug development for customers from the earliest stages of discovery all the way through IND.
-
This new partnership combines world-class toxicology services with proprietary, state-of-the-art biological engineering capabilities and represents a significant milestone toward establishing one of the first fully integrated biological services partnership for antibodies and other protein therapeutics. In addition, the international reach of these preferred contract research organizations brings much needed cost-effective integrated services for pharmaceutical development.
-
About Charles River
Charles River, headquartered in Wilmington, MA, provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its approximately 8,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. For more information, visit www.criver.com.
-
About BioAtla
BioAtla, LLC, is a global biology outsourcing services provider based in San Diego, CA, with research operations in San Diego, New York and Beijing. BioAtla provides an extensive range of protein therapeutic services that include target discovery, humanization, fully human antibody generation, affinity maturation, conditional biologic generation, expression optimization, enzyme engineering, pathway engineering, epitope mapping and more. They are a pioneer in BioAcceleration™, using a global infrastructure to deliver cost-efficient access to state-of-the-art technologies and services and maximizing antibody and other protein product development opportunities for their client partners.
-
For more information, please visit www.bioatla.com or contact
-
Carolyn Anderson
Executive Vice President
BioAtla, LLC
10190 Telesis Court
San Diego, CA 92121
858-558-0708 ext. 0
info@bioatla.com
-
SOURCE BioAtla, LLC / Charles River Laboratories International, Inc.
Nov 8, 2010 | BioAtla Redefining the Business of Drug Discovery
– Company offers biotech firms new opportunities in wake of troubled global economy –
SAN DIEGO, Calif., November 8, 2010. BioAtla, LLC, a San Diego-based protein therapeutics services provider, wants drug discovery companies worldwide to know one thing about operating in today’s business climate – there is hope. While biotechnology companies tackle the traditional complexities of scientific discovery, they must also navigate amidst increasing business pressures fueled by rising costs and scarce funding. That’s where BioAtla thrives.
BioAtla helps biotechnology companies propel drug development forward by bringing a pioneering spirit that welcomes unique collaborations, backed by an expanding global infrastructure. Their business philosophy is simple: empower biotech firms with the scientific expertise they need, at a cost they can afford. How BioAtla achieves this is part art, and definitely part science.
“We offer leading-edge, comprehensive protein engineering services performed in China, which gives our clients cost-efficient access to technologies that would otherwise be unaffordable,” says Dr. Jay M. Short, Founder, Chairman and CEO of BioAtla. “Our corporate policy is to assign 100% ownership of products resulting from BioAtla services to our customers. And our technologies are proprietary, strengthening our clients’ intellectual property portfolios along the way. We help your organization create it, make it and own it.”
Dr. Short is no stranger to innovation. He’s the Founder and former CEO, President and CTO of Diversa Corporation (now British Petroleum and Verenium), where he achieved the largest biotech IPO at the time. He also served as President of Stratacyte, and VP of R&D and Operations for Stratagene Cloning Systems (now Agilent). With BioAtla, Dr. Short continues to push the envelope of innovative and proprietary technologies in the field of protein therapeutics. BioAtla’s CIAO!™ (Comprehensive Integrated Antibody Optimization™) technology platform for protein expression can select molecules in a manner that mirrors both the body’s environment and the host that will be used for final manufacturing of the drug – reducing downstream drug risk from early in the discovery process. And the company is pioneering “Only at BioAtla” services such as its recently launched Native Target Discovery™ platform.
While the company is garnering attention for its comprehensive scientific expertise, BioAtla is also making business collaborations that accelerate drug development a real art form. “Financial collaborations are rapidly replacing traditional drug discovery business models that simply are not longer financially sustainable. We’re not only willing, but highly interested in establishing a financial partnership to accelerate your company’s success,” says Dr. Short. One such collaboration is the partnership between BioAtla and Femta Pharmaceuticals; the two companies share a technology platform with BioAtla fulfilling the role of a services company while Femta seeks to develop therapeutic candidates.
Recently, BioAtla has taken their unique business approach to the web. Their newly branded website (http://www.bioatla.com) is organized to educate the user not only about the services the company is offering, but where the industry is headed. There is hope for a better drug discovery process. BioAtla calls it BioAcceleration™ and they are proving it works. The website was custom created for BioAtla by San Diego-based brand communication firm, Miriello Grafico. Some unique features of the site include a section about global collaboration, illustrating how the company works with their internationally located facilities to ensure quality and transparency, as well as an educational appendix section. In celebration of the website launch, BioAtla is offering visitors the opportunity to register-to-win a free 3G iPad with pre-loaded apps valued at $100. The contest runs through November 30, 2010.
-
About BioAtla, LLC
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with research operations in San Diego, New York, Beijing and expanding in 2011. They are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for their client partners. BioAtla translates industry know-how and thought leadership into tangible results for their clients.
For more information, please visit www.bioatla.com or contact
Carolyn Anderson
Executive Vice President
BioAtla, LLC
10190 Telesis Court
San Diego, CA 92121
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Oct 7, 2010 | BioAtla introduces GigaMab™ Fully Human Antibody Platform
– New platform takes HuAb to the next level –
SAN DIEGO, Calif., October 7, 2010. BioAtla, LLC, announced a new Fully Human Antibody Platform with full-length antibodies and over 10^9 members expressed in mammalian cells. This proprietary, expanded and validated high diversity HuAb library is immediately available to BioAtla’s client partners.
The platform maintains the same screening timeframes of traditional methods while capitalizing on one of the most proven and safe glycosylating systems, reducing the potential for negative immunogenicity.
For more information, visit our GigaMab™ Fully Human Library informational page.
-
About BioAtla, LLC.
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Aug 27, 2010 | BioWorld Today cites innovative BioAtla/Femta collaboration
– Industry publication recognizes our unique collaboration with Femta –
An article appearing in the August 27, 2010 edition of BioWorld Today by Catherine Shaffer calls attention to the unique business partnership and shared technology platform between BioAtla (service provider) and Femta Pharmaceuticals (therapeutics discovery).
The article also refers to BioAtla as a contender for providing “best-in-class” antibodies via usage of rabbit physiology.
Read the entire article (Apexigen Exploits Unique Rabbit Physiology to Make Antibodies) by downloading the PDF.
Aug 2, 2010 | BioAtla inks 25th partnership, looks to continued growth
– Company that began in 2007 rapidly gains acceleration –
SAN DIEGO, Calif., August 18, 2010. BioAtla, LLC, announced the signing of its 25th partnership with institutions that include private and public companies and venture capital groups and academia from the across the US, Europe, Israel and South Korea.
The company continues to accelerate its expansion based on its unique combination of state-of-the-art technologies embedded into services that allow its clients to save costs and speed their development time to market.
A global outsourcing model has been embraced by many leading biotech companies and BioAtla is guiding these companies with best practices for overseas discovery and development.
-
About BioAtla, LLC.
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Feb 3, 2010 | San Diego Science Festival recipient of BioAtla goodwill
– Student festival gets boost from real world scientists –
SAN DIEGO, Calif., February 3, 2010. BioAtla, LLC, announced their continued support for the San Diego Science Festival, pledging both a monetary donation and a commitment to serve on the honorary board of directors.
Dr. Jay M. Short, CEO and Founder of BioAtla, will serve on the board along with Drs. Roger Tsien, Maryanne Fox, Craig Venter and other biotechnology veterans. BioAtla has been an active supporter of the festival that began in 2009. The festival includes hundreds of science-related school activities and public events, culminating in an annual Expo Day, noted as the largest single day celebration of science in the nation.
-
About BioAtla, LLC.
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Jan 19, 2010 | Halozyme announces research alliance with BioAtla
– Conditionally active biologics a centerpiece of the three year agreement –
In a recent statement – dateline SAN DIEGO, January 19, 2010 – Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation.
During the initial three year term of the research collaboration, Halozyme will receive exclusive worldwide commercial rights from BioAtla to conditionally active biologics (CABs) that arise from the agreement.
For more details, download a PDF of the company’s entire press release here.
Dec 15, 2009 | BioAtla partner company to manufacture with Lonza
– Femta/Lonza targeting Rheumatoid Arthritis treatment –
BioAtla’s partner company, Femta Pharmaceuticals, recently announced an agreement with Lonza Group Ltd.
In a joint release by Femta Pharmaceuticals and Lonza – dateline San Diego, CA / Basel, Switzerland, 15 December 2009 – Femta Pharmaceuticals and Lonza Group Ltd announced the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101.
FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis. The agreement allows Femta access to Lonza’s GS Gene Expression System™.
For the entire release, download a PDF here.
Read more about Femta in the Wall Street Journal here.
Jun 11, 2009 | BioAtla announces novel system for optimizing proteins
– Say hello to Comprehensive Integrated Antibody Optimization: CIAO! –
SAN DIEGO, Calif., June 11, 2009. BioAtla, LLC, announced a system for optimizing proteins, including antibodies for maximal expression and physiological function, dubbing the system CIAO!
The acronym stands for Comprehensive Integrated Antibody Optimization and represents the first demonstrated, fully integrated protein discovery, evolution and manufacturing system for protein therapeutics.
While protein engineering has traditionally been accomplished via systems that were simplest to work with, but not necessarily optimal for production, CIAO! eliminates the need to compromise. The system allows for selection of molecules in an environment that is both natural origin (i.e. mammalian cells) and optimized from the very beginning for their function and expression.
BioAtla has successfully demonstrated CIAO! from discovery through clinical scale manufacturing. This patent pending development and manufacturing technology is expected to speed protein therapeutic development and improve clinical efficacy.
Learn more at our CIAO! page.
-
About BioAtla, LLC.
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
May 24, 2008 | Fully human antibody library introduced by BioAtla
– Innovative full-length IgG library expressed in Mammalian cells –
SAN DIEGO, Calif., May 24, 2008. BioAtla, LLC, announced the release of their proprietary fully human antibody library. HuAb-SD rapidly identifies antibodies for customer targets and reduces the time for generating promising therapeutic lead molecules. HuAb is completely compatible with BioAtla’s affinity maturation and expression platforms. Expressed in mammalian cells, the library allows customers to bypass many problems encountered with traditional techniques used in antibody engineering.
About BioAtla, LLC.
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and in 2011, Shanghai, China. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
May 10, 2008 | BioAtla founds Femta Pharmaceuticals
– Ongoing collaboration to fuel growth of both companies –
SAN DIEGO, Calif., May 10, 2008. BioAtla, LLC, has joined with Latterell Venture Partners to launch Femta Pharmaceuticals, an antibody development company. Femta’s initial drug pipeline was developed by BioAtla to deomonstrate the power of its technology platforms. Since BioAtla was established as a dedicated service provider, the formulation of Femta Pharmaceuticals allows BioAtla to maintain its service focus.
BioAtla also established an exclusive relationship to supply Femta with advanced protein engineering technologies to bioaccelerate™ Femta’s antibody development program. BioAtla’s proprietary ATLab™ technology platform was a key driver in the agreement. Contractual details remain confidential.
About BioAtla, LLC
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and in 2011, Shanghai, China. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
About Femta Pharmaceuticals
Femta Pharmaceuticals is focused on the development of best in class therapeutic monoclonal antibodies for the treatment of various disease states. Our monoclonal antibodies have applications in the areas of inflammation, autoimmune disease andoncology. Femta develops high affinity, high specificity monoclonal antibodies withimproved effector functions as well as favorable safety and pharmacokinetic profiles. This is accomplished using proprietary protein engineering technology from BioAtla. The technology enables Femta to develop super high affinity humanized and/or human antibodies (sub pico molar to femto molar affinity) to potentially any target that meets our selection criteria. The high affinity of our antibodies will contribute to making our products more efficacious with better safety profiles, as well as potentially reducing drug dosage.
For more information, please visit www.bioatla.com or contact
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Jan 18, 2008 | BioAtla appoints Leslie Hickle as VP of Business Development
– Biotech industry veteran to support company growth –
SAN DIEGO, Calif., January 18, 2008. BioAtla, LLC, announces the addition of Leslie A. Hickle, Ph.D. as Vice President of Business Development for the West Coast. Dr. Hickle brings to BioAtla more than 20 years of industry leadership, and will concentrate on connecting drug discovery companies with the comprehensive services and “can do” BioAcceleration™ philosophy that enables clients of BioAtla to propel their drug discovery efforts forward.
“Leslie’s experience with start-up biotech companies and notable success developing new companies for growth make her perfectly suited to BioAtla’s mission,” said Jay M. Short, Ph.D., CEO and Founder of BioAtla. “At this time in our company’s development, Leslie’s depth of technical experience and product positioning add immense value to our executive team.”
About BioAtla, LLC
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Jun 10, 2007 | BioAtla launches suite of antibody engineering tools
– Introduction of ATLab™ technologies is company’s latest breakthrough –
SAN DIEGO, Calif., June 10, 2007. BioAtla, LLC, today announced the release of a validated suite of tools to bioaccelerate™ antibody evolution and humanization of nonhuman antibodies. Coined ATLAb™, the platform provides rapid humanization of non-human antibodies, and has proven utility in improving antibody affinity, specificity, effector function, expression level, stability and solubility. The technology suite includes ATLAb™ Antibody Humanization, ATLAb™ Antibody Evolution and ATLAb™ Antibody Expression and Purification.
Jay M. Short, Ph.D., CEO and Founder of BioAtla stated that in addition to ATLab™, BioAtla’s Humanation™ technology allows for the evolution of mouse or other non-human antibodies info fully human antibodies. These fully human antibodies contain only human sequence and no mouse or non-human antibody sequence – while maintaining similar specificity as the starting antibody.
About BioAtla, LLC
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and in 2011, Shanghai, China. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC
Apr 6, 2007 | BioAtla signs Capia IP as exclusive provider for intellectual property services
– IP firm key contributor to business strategy, client satisfaction of BioAcceleration™ company –
SAN DIEGO, Calif., April 6, 2007. Capia IP has been retained to provide business, licensing, legal options and intellectual property support for BioAtla’s BioAcceleration™ protein therapeutics services business.
Ms. Carolyn Anderson, founder of Capia IP, stated “more and more companies understand that intellectual property strategy is a key component of business strategy. IP is literally the company’s jewels and the early discussion and implementation of IP strategy can add tremendous assets to a company’s portfolio as well as reduce long term costs by identifying and reducing unnecessary and distracting issues.”
Capia IP expertise ranges from biotechnology, pharmaceutical, agricultural, chemical and industrial technologies.
The two companies expect that their collaboration will allow rapid analysis and identification of potential issues for both BioAtla’s internal programs and partnering projects.
About BioAtla, LLC
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and in 2011, Shanghai, China. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
About Capia IP
Capia IP collaborates with enterprises and individuals in life sciences to strategically manage and maximize the value of their intellectual property needs in view of their business. As a dedicated business partner of BioAtla, LLC, Capia IP offers BioAtla client partners comprehensive IP services to create, own and protect their results.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info@bioatla.com
SOURCE BioAtla, LLC / Capia IP
Mar 29, 2007 | BioAtla establishes new contract business platform for protein engineering
- Company launched as sister company to BioDuro for protein therapeutics -
SAN DIEGO, Calif., March 29, 2007. BioAtla announced that its operations in San Diego and Beijing will be the first to provide global contract services solely focused on protein therapeutics.
Founded by Dr. Jay M. Short, Dr. Masood Tayebi and Carolyn Anderson, the company is following the successful strategy implemented by their earlier sister company, BioDuro, who found that it could increase the odds of success for early stage biotech companies by allowing them to outsource several key functions in combinatorial chemistry and clinical trials.
Protein therapeutics, specifically antibodies, is the fastest growing sector of the pharmaceutical industry. BioAtla’s 4th generation protein optimization technologies combined with a multinational professional staff will enable biotech startups and major pharmaceutical companies to cost effectively accelerate their protein-based drug programs.
About BioAtla, LLC
BioAtla, LLC is a global, biology outsourcing services provider based in San Diego, CA with significant research operations in San Diego, New York, Beijing and expanding in 2011. We are a pioneer in BioAcceleration™ – using a global infrastructure to deliver cost-efficient access to state-of-the art technologies and services, maximizing antibody and other protein product development opportunities for our client partners.
Our exclusive manufacturing partnership with China-based BioDuro, a PPD company, and our intellectual property partnership with Capia IP translates our industry know-how and thought leadership into tangible, ownable results for our clients.
For more information, please visit www.bioatla.com or contact:
Carolyn Anderson, Executive Vice President
BioAtla, LLC
858-558-0708
info@bioatla.com
SOURCE BioAtla, LLC
Mar 3, 2007 | Industrial Biotechnology profiles BioAtla founder, Dr. Jay M. Short
– Dr. Short the subject of sustainable bioscience article –
Leading industry publication, Industrial Biotechnology, recently profiled BioAtla founder, Dr. Jay M. Short. The article – titled “Diversity in vision and expertise: Jay Short promotes sustainable bioscience” – discusses some of Jay’s recent accomplishments and offers his perspective on meaningful success in the bioscience industry. Read the article at liebertonline.com
Aug 15, 2011 | BioAtla Partner Femta Pharmaceuticals Announces IND Filing of FM101
SAN DIEGO, Calif., Aug 01, 2011
Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).
FM101 is part of a novel class of immune modulators that inhibit the action of the pro-inflammatory cytokine IL-6. IL-6 has been shown to be a major player in the etiology of a number of inflammatory diseases. Pre-clinical studies have shown that FM101 is effective in inhibiting IL-6 both in vivo and in vitro. GLP toxicology studies have shown FM101 to be safe and well tolerated at doses at least as high as 100mg/kg.
The proposed Phase I study entitled “A Multicenter, Randomized, Double‑Blind, Placebo Controlled, Phase 1 Safety and Preliminary Efficacy Study of FM101 in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy” is designed to evaluate the safety and tolerability of increasing and multiple doses of the FM101 in patients with moderate to severe RA.
RA is a progressive and debilitating disease of unknown etiology that results in destruction of the synovial joints and has a worldwide distribution with an estimated prevalence of 1 to 2%. Prevalence increases with age, approaching 5% in women over 55 years. The average annual incidence in the United States (US) is about 70 per 100,000 annually for a total of 1.3 million Americans ≥18 years of age. Both incidence and prevalence of RA are two to three times greater in women than in men and about 80% of patients develop RA between ages 30 and 60. The cost of RA in the US is approximately $128 billion per year in medical care and lost wages and productivity. In addition to the high economic cost, RA also accounts for 22% of all deaths from arthritis, and people with RA are more likely to die than persons of the same age in the general population.
About FM101
FM101 is a recombinant humanized monoclonal antibody directed against a neutralizing epitope on human IL‑6. IL‑6 is a pro-inflammatory molecule that is found in the joints of RA patients and contributes to the pain, joint destruction and chronic inflammation commonly seen in this population. Pre-clinical studies have shown that FM101 is effective in inhibiting IL-6 in a number of in vitro and in vivo models.
About Femta
Femta Pharmaceuticals is focused on the rapid and cost effective development of highly effective and competitive therapeutic monoclonal antibodies for the treatment of various disease states. Our monoclonal antibodies have applications in the areas of inflammation, autoimmune disease and oncology. Femta develops high affinity, high specificity monoclonal antibodies with improved effector functions as well as favorable safety and pharmacokinetic profiles. The high affinity of our antibodies will contribute to making our products more efficacious with better safety profiles, as well as potentially reducing drug dosage. Femta’s product candidates and programs are protected by the company’s extensive global intellectual property portfolio. More information about Femta can be found at www.femtapharma.com.
–
Oct 6, 2010 | BIG launches a BioAtla sister company, Molecular Response
The BioAtla family is growing again! Our key investor, B.I.G. has announced the launch of a new therapeutics company, Molecular Response. A detailed release was recently issued and appears below:
– Molecular Response launches west coast operations –
San Diego, CA, July 6, 2010 – Molecular Response, a privately held contract research and development organization and a leader in identification of target populations for personalized medicine and drug development partners, today announced the opening of new facilities at 10865 Road to the Cure, in San Diego, California.
“We are very bullish on the launch of our operations in the heart of San Diego’s biotechnology center, one of the key centers of excellence for innovative ideas and technology in the areas of research, diagnostics, and therapeutics” said Chairman and CEO, Dr. Masood Tayebi. “We have built a world class facility to both provide clinical trial support services to our biopharmaceutical partners and to advance the growing market for targeted therapeutics and personalized medicine, through strategic collaborations with centers of innovation here in San Diego.”
About Molecular Response
Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.
For additional information, please visit www.molecularresponse.com
Jan 1, 2011 | Click here for BioAtla’s 2011 Calendar of Events
• June 27-30, 2011: Join us for the 2011 BIO International Convention, in Washington, DC at the Walter E. Washington Convention Center.
• March 14-16, 2011: Join us for BIO-Europe Spring 2011, in Milan, Italy at the Milano Convention Center.
-
• Check back for periodic event listing updates.
Jan 1, 2011 | BioAtla PDF Library
Learn more about the following topics by clicking to download a PDF:
BioAtla’s Antibody Brochure
BioAtla’s Protein Evolution Brochure
Educational Topics:
Antibody Isotypes
Antibody Nomenclature
Antibody Structure
Clinical Process
Scientific Glossary
BioAtla Services:
Affinity Maturation
CIAO!™
Class Switch™
Express Humanization™
Follow-On Biologics: Biosimilars
Follow-on Biologics: Biobetters
GigaMab™ Fully Human Library
MIRAC™ Proteins
Multisite Protein Evolution™
Native Target Discovery™
Preclinical